Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome
- 9 February 2026
- journal article
- research article
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (3) , 283-296
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary InterventionJACC: Cardiovascular Interventions, 2024
- Genotype-Guided Antiplatelet TherapyJACC, 2024
- Real-World Implementation of a Genotype-Guided P2Y12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome PatientsJACC: Cardiovascular Interventions, 2024
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 UpdateClinical Pharmacology & Therapeutics, 2022
- 2021 ACC/AHA/SCAI Guideline for Coronary Artery RevascularizationJACC, 2022
- Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor TherapyJACC: Cardiovascular Interventions, 2021
- Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary InterventionJAMA, 2020
- Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMIJACC: Cardiovascular Interventions, 2020
- One-stage individual participant data meta-analysis models: estimation of treatment-covariate interactions must avoid ecological bias by separating out within-trial and across-trial informationStatistics in Medicine, 2016
- Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differStatistics in Medicine, 2016